Worldwide Clinical Trials Holdings, Inc.

Based in the US, Worldwide Clinical Trials Holdings, Inc. is a global Contract Research Organization (CRO) dedicated to providing comprehensive solutions for drug development through tailored clinical trial services. Worldwide Clinical Trials Holdings, Inc. , founded in 1986, operates as a global CRO offering specialized services for drug development.

The company is headquartered in the US. Neal Cutler and Peter Benton serve as CEOs. In August 2023, Kohlberg & Company agreed to acquire a majority stake in the firm as part of a recapitalization transaction with The Jordan Company. The company has completed a total of 5 deals, with the most recent deal occurring on 2023-08-07.

Worldwide Clinical Trials operates as a global Contract Research Organization (CRO) specializing in tailored solutions for drug development. The company offers a comprehensive range of services designed to support the entire clinical trial lifecycle, including clinical monitoring, site management, data management, and patient recruitment across diverse therapeutic areas such as rare diseases, oncology, neuroscience, and cardiovascular and metabolic disorders. Their core offerings provide personalized attention to each study, ensuring customized solutions for clients in the pharmaceutical and biotechnology sectors. The company serves a global client base, with notable engagement in markets across North America, Europe, and Asia, facilitating drug development programs aimed at advancing life-saving treatments.

Their expertise spans over 30 years, providing clients with access to senior-level experts throughout the drug development process. Worldwide Clinical Trials generates revenue through collaborative partnerships with clients in the pharmaceutical and biotechnology sectors. The business model includes structured transactions, such as fixed-fee agreements or milestone-based payments, reflecting the specific requirements of each clinical study. Revenue is derived from various service offerings, including phase I-IV clinical trials, bioanalytical lab services, and real-world evidence studies, with pricing structures aligned to the complexity and duration of the clinical trials undertaken.

The company’s commitment to tailored solutions ensures effective connectivity between the firm’s scientific and operational experts and its clients, enhancing the overall value of partnerships in the drug development ecosystem. As part of its future growth strategy, Worldwide Clinical Trials will leverage the acquisition by Kohlberg & Company to accelerate its growth initiatives. The focus will include the development of new products designed to enhance their clinical services, although specific launch dates are not provided. The company is also planning to expand its operations into additional geographic markets, particularly targeting regions in Europe and Asia by 2025.

The recent funding from the acquisition will support these expansion efforts, reinforcing the company's capabilities and market presence.